Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A- responsive cervical dystonia

Neurology

Volumn 53, Issue 7, 1999, Pages 1439-1446

  Brashear, A ^a   Lew, M F ^b   Dykstra, D D ^c   Comella, C L ^d   Factor, S A ^e   Rodnitzky, R L ^f   Trosch, R ^g   Singer, C ^h   Brin, M F ⁱ   Murray, J J ^j   Wallace, J D ^k   Willmer Hulme, A ^k   Koller, M ^k  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^g Sinai Clin Neurosci Res Center   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ MOUNT SINAI MEDICAL CENTER   (United States)

^j PRA International USA   (Netherlands)

^k Athena Neurosciences Inc   (United States)

more..

Author keywords

Botulinum toxin type B; Cervical dystonia; Clinical trials; NeuroBloc

Indexed keywords

BOTULINUM TOXIN B; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CERVICAL SPINE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPHAGIA; DYSTONIA; FEMALE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NECK PAIN; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TORTICOLLIS; XEROSTOMIA;

EID: 0032718516     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1439     Document Type: Article

References (31)

1. Tsui J, Eisen A, Stoessel AJ, et al. Double-blind study of botulinum toxin and spasmodic torticollis. Lancet 1986;2:245-246.
2. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
3. Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol 1993;33:199-203.
4. Moore AP, Blumhardt LD. A double-blind trial of botulinum toxin "A" in torticollis with one year follow up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
5. Green P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
6. American BotB Cervical Dystonia Study Group. BotB (botulinum toxin type B) in the treatment of cervical dystonia - protocol AN072-008: an interim analysis. Mov Disord 1995; 10:372. Abstract.
7. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-707.
8. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effect botulinum toxin in human. Neurosci Lett 1997;24:91-94.
9. Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. Mov Disord 1993;8:479-483.
10. Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 1998;64:577-580.
11. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions, and antibodies. In: Moore P, ed. Handbook of botulinum toxin treatment. London: Blackwell Science, 1995:16-27.
12. Das Gupta BR, Sugiyama H. Molecular form of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immunol 1976;14:680-686.
13. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-194.
14. Siegel LS. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid. J Clin Microbiol 1989;27:1906-1908.
15. Schiavo G, Benefenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
16. Green P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
17. Jankovic J. Treatment of dystonia. In: Watts RL, Koller WC, eds. Movement disorders: neurological principles and practice. New York: McGraw-Hill, 1997:443-454.
18. Mezaki T, Kaji R, Hamano T, et al. Optimisation of botulinum treatment for cervical and axial dystonias: experience with Japanese type A toxin. J Neurol Neurosurg Psychiatry 1994; 57:1535-1537.
19. Ludlow CL, Hallett M, Rhew K, et al. Therapeutic use of type F botulinum toxin. N Engl J Med 1992;362:349-350.
20. Greene P, Fahn S. Treatment of torticollis with injections of botulinum toxin type F in patients with antibodies to botulinum toxin type A. Mov Disord 1992;7:134. Abstract.
21. Consky ES, Basinski A, Belle L, et al. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1991;40:445. Abstract.
22. Consky ES, Lang AE. Assessment of cervical dystonia: the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin, neurological disease and therapy series. Vol. 25. New York: Marcel Dekkar, 1994:224-226.
23. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed., vol. 1. Cary, NC: SAS Institute, 1989:943.
24. SAS Institute Inc. SAS/STAT user's guide, version 6. 4th ed., vol. 2. Cary, NC: SAS Institute, 1989:846.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1996;50:163-170.
27. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972;34:187-220.
28. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163.
29. Cullis PA, O'Brien CF, Truong DD, Koller M, Villegas TP, Wallace JD. Botulinum toxin type B: an open label, dose escalation, safety and preliminary efficacy study in cervical dystonia patients. In: Fahn S, Marsden CD, DeLong M, eds. Dystonia 3 - advances in neurology. Vol. 78. Philadelphia: Lippincott-Raven Publishers, 1998:227-230.
30. Truong DD, Cullis PA, O'Brien CF, et al. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients. Mov Disord 1997;12:772-775.
31. Tsui JKC, Hayward M, Mak EKM, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995;45:2109-2110.